Building on this evolving immunotherapy landscape, six-transmembrane epithelial antigen of prostate 1 (STEAP1) has emerged as a promising immunotherapeutic target for mCRPC because of its selective tumor expression and accessible cell-surface localization [156]. Here, STEAP1 is linked to neoplasm.